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DiGeorge syndrome, caused by a 22q11 micro-
deletion or mutation of the TBX1 gene, varies in
severity greatly, even among monozygotic twins.
Epigenetic phenomena have been invoked to explain
phenotypic differences in individuals of identical
genetic composition, although specific chromatin
modifications relevant to DiGeorge syndrome are
elusive. Here we show that lack of the histone
acetyltransferase MOZ (MYST3/KAT6A) pheno-
copies DiGeorge syndrome, and the MOZ complex
occupies the Tbx1 locus, promoting its expression
and histone 3 lysine 9 acetylation. Importantly,
DiGeorge syndrome-like anomalies are present in
mice with homozygous mutation of Moz and in
heterozygous Moz mutants when combined with
Tbx1 haploinsufficiency or oversupply of retinoic
acid. Conversely, a Tbx1 transgene rescues the
heart phenotype in Moz mutants. Our data reveal
a molecular mechanism for a specific chromatin
modification of the Tbx1 locus intersecting with an
environmental determinant, modeling variability in
DiGeorge syndrome.
INTRODUCTION
DiGeorge/velo-cardio-facial/22q11 deletion syndrome (DGS,
VCFS, 22q11 delS) is the most common deletion syndrome in
humans (Singh et al., 2002) and is characterized by severe
cardiac and aortic arch defects, thymus dysplasia, cleft palate,
and craniofacial abnormalities (Lindsay, 2001). Despite its char-
acteristic genetic lesion, the syndrome shows a remarkable vari-
ability in phenotypic severity. Newborn infants who lack the
same 22q11 deletion interval can present with severe aortic
arch and heart defects requiring surgery or, alternatively, have
no detectable cardiovascular defects. Even monozygotic twins
can exhibit this level of discordance, suggesting that the pheno-
typic variability cannot be explained on the basis of genetic652 Developmental Cell 23, 652–663, September 11, 2012 ª2012 Elsdifferences alone (Goodship et al., 1995). As a consequence,
chromatin modifiers are of great interest because they have
the potential to integrate environmental effects and directly alter
expression levels of key regulators of aortic arch and heart
development.
Among the genes in the 1.5–3Mb hemizygous deletion interval
on chromosome 22q11 causing DGS, the TBX1 gene is a major
contributor to the characteristic clinical features seen in patients.
The TBX1 gene encodes a T box DNA-binding transcription
factor, and mutations in one allele of the TBX1 gene can lead
to the same syndrome without 22q11 deletion (Paylor et al.,
2006; Stoller and Epstein, 2005; Torres-Juan et al., 2007; Yagi
et al., 2003; Zweier et al., 2007). Furthermore, heterozygous
mutations of the Tbx1 gene in mice model DGS (Jerome and
Papaioannou, 2001; Lindsay et al., 2001; Merscher et al.,
2001). We show here that a chromatin modifier, the monocytic
leukemia zinc finger protein (MOZ/MYST3/KAT6A), is a critical
regulator of the Tbx1 gene in vivo.
MOZ, a member of the MYST family of histone acetyltrans-
ferases (Reifsnyder et al., 1996; Thomas and Voss, 2007; Voss
and Thomas, 2009), was first identified as a target of recurrent
translocations causing a particularly aggressive form of acute
myeloid leukemia (Borrow et al., 1996). The Moz gene is ex-
pressed widely at moderate levels (Thomas et al., 2006; Voss
et al., 2009), but mutation of the Moz gene has surprisingly
specific effects. MOZ is required for the development of hemato-
poietic stem cells (Katsumoto et al., 2006; Thomas et al., 2006),
thymus development (Thomas et al., 2006), histone 3 lysine 9
(H3K9) acetylation, and transcriptional activity at Hox gene loci
and body segment identity specification (Voss et al., 2009).
Through the use of Moz and Tbx1 mutant mice, expression
analysis, chromatin immunoprecipitation (ChIP), and pharmaco-
logical treatment, we report here a role of MOZ in cardiac,
pharyngeal apparatus, and facial development. We show that
MOZ is required for H3K9 acetylation (H3K9ac) and transcription
at the Tbx1 locus in vivo, and not essential for a range of other
loci regulating cardiac development. Significantly, we demon-
strate that Moz mutation leads to the spectrum of defects seen
in DGS, that a Tbx1 transgene rescues the heart defects in
Moz mutant mice, that Moz exhibits synergistic genetic interac-
tion with Tbx1, and that Moz haploinsufficiency synergizes with
oversupply of retinoic acid (RA).evier Inc.
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Moz Deficiency Leads to Anomalies Characteristic
of DGS and Tbx1 Deficiency
TwoMozmutant alleles were used in this study:MozD andMoz.
The carboxy-terminal deletion allele, MozD, does not produce
detectable protein, as examined by immunoblotting (Thomas
et al., 2006). MozD/D homozygous mice are born at a normal
Mendelian ratio and die within the first hour after birth. In the
Moz allele exons 3–7 were deleted (Voss et al., 2009). Moz/
embryos die between embryonic day 14.5 (E14.5) and birth,
depending on the genetic background. Homozygosity of either
allele causes the absence of transplantable hematopoietic stem
cells (Thomas et al., 2006; unpublished data), anterior homeotic
transformation (Voss et al., 2009), and the defects reported
here. Based on the differences in time of death and in the severity
of the defects between the two alleles, the Moz allele is the
more severe loss-of-function allele, and it is inferred that the
MozD allele must produce some residual, albeit not detectable
and truncated, MOZ protein. MozD/D homozygotes were used
to study the full spectrum of anatomical defects at birth, and
Moz/ homozygotes were used for biochemical studies.
Newborn MozD/D mice (33 of 33) were of normal size. The
morphology and histology of most organs were normal.
However, all MozD/D mutant newborn pups had micrognathia
(Figures 1A and 1B) and cleft palate (Figures 1C–1F; see Fig-
ure S1 available online; Table 1). In addition, we have previously
reported the absence or hypoplasia of the thymus in 100% of
MozD/D mutant newborn pups (Thomas et al., 2006).
Macroscopic examination, ink injection, and resin casting
showed thatMozD/Dmutants most commonly exhibited an inter-
rupted aortic arch between the left common carotid artery and
the left subclavian artery, i.e., interrupted aortic arch type B
(IAA-B) (74%; Figures 1G–1J; Table 1). In this condition, the
ascending aorta is not connected to the descending aorta
(Figures 1H and 1J). In 26% of MozD/D mutants, the pulmonary
trunk was curved to the right side, forming an abnormal right
aortic arch and a right descending aorta (Figure S1). Other
abnormalities observed included retropharyngeal/retrotracheal
right subclavian artery (RSA), abnormal origin of the RSA, and
incompletely remodeled great vessel walls, which appear dilated
in diameter and thin walled (Figure S1). The aortic arch defects in
MozD/D newborn pups closely resembled anomalies observed in
patients with DGS and reported inmice in an allelic series of Tbx1
mutations (Table 1).
Ink injection into the inferior vena cava and resin casts of the
heart cavities (Figures 1K–1M) showed that 95% of MozD/D
mutant newborns lacked separation of the left and right side of
the heart at the level of the ventricles (n = 19 MozD/D, 16
MozD/+, and 17 Moz+/+ newborn pups). Some MozD/D mutant
newborns showed atrial septal defects in addition (Table 1).
Serial histological sections showed overriding aorta and ventric-
ular septal defects (VSDs) of varying severity affecting either
large parts of the septum (Figures 1N and 1O) or the superior,
membranous part of the ventricular septum (Figure S1). Varying
degrees of cardiac defects are also observed in approximately
80% of patients suffering from DGS (Table 1).
Overall, MozD/D mutant newborn mice exhibited the full spec-
trum of facial, palatal, thymic, aortic arch, and cardiac septalDevelopmendefects described in DGS and encompass defects observed in
mice in a series of Tbx1 mutant alleles (Table 1; Botto et al.,
2003; Jerome and Papaioannou, 2001; Kobrynski and Sullivan,
2007; Lindsay et al., 2001; Merscher et al., 2001; Singh et al.,
2002; Vitelli et al., 2002; Xu et al., 2004; Yagi et al., 2003; Zhang
and Baldini, 2008).
Embryonic Pathogenesis of theMoz Mutant Aortic
Arch Defects
Examination of the developmental origin of the aortic arch
defects uncovered a failure in fourth pharyngeal arch artery
(PAA) development. Between E9.5 and E10.5 (4–5 weeks in
human), the fourth PAAs develop. Between E10.5 and E12.5
(5–8 weeks in human), asymmetric remodeling of the PAAs
begins and results in the formation of the aortic arch from the
fourth PAA on the left side of the body, which then connects
the ascending aorta to the descending aorta (Figures 1P–1R).
Although the aorta/PAA system was normal in MozD/D embryos
at E9.5 (Figures 1S and 1T; overview in Figure S1), the fourth
PAA had failed to develop on the left side in E10.5 MozD/D
embryos (Figures 1U–1X), resulting in the failure to connect the
ascending and descending aorta (interrupted aortic arch;
Figures 1J and 1R). The fourth PAA on the right body side is
reduced in diameter in MozD/D embryos (Figure S1).
We conclude that the aortic arch anomalies observed in
MozD/Dmutant newborn arise from a failure of fourth PAA devel-
opment between E9.5 and E10.5. Hypoplasia or aplasia of the
fourth PAA at E10.5 has been described as the ‘‘hallmark of
Tbx1 haploinsufficiency’’ (Randall et al., 2009).
T box Gene Expression Is Reduced in Moz-Deficient
Embryos
Three findings suggested that the pathogenic mechanism of
the Moz mutant phenotype involved the Tbx1 gene: (1) the
Moz loss-of-function defects were similar to the anomalies
observed in patients with DGS; (2) the Moz loss-of-function
defects encompassed those reported in mice within an allelic
series of Tbx1 mutation; and (3) based on our previous study of
the role of MOZ in the regulation of Hox gene expression,
we postulated that the expression of putative MOZ target
gene(s) responsible for the velo-cardio-facial anomalies may
only be reduced by approximately one-half. Because haploid
mutation of the TBX1 gene in humans can cause DGS
(Paylor et al., 2006; Stoller and Epstein, 2005; Torres-Juan
et al., 2007; Yagi et al., 2003; Zweier et al., 2007), we determined
mRNA expression levels of the Tbx1 gene in Moz mutant
and control embryos. In addition, we determined expression
of the immediate genomic neighbors of Tbx1 (Figure 2A;
Gnb1l, Gp1bb, Sept5) and another gene deleted in the larger
22q11 deletion interval, Crkl, because homozygous mutations
in Crkl in mice cause DGS-like defects (Guris et al., 2001).
Furthermore, we examined genes encoding other transcription
factors involved in heart development (Figure 2B; Nkx2.5,
Gata4, Tbx2, Tbx5, Tbx20, Pitx2, Foxa2, Foxc1, Foxc2), along
with other genes encoding T-box proteins for comparison
(Tbx3, Tbx4) and three housekeeping genes (Pgk1, Hsp90ab1,
Gapdh).
Tbx1 was the only one of seven genes examined at E8.5 that
showed significantly reduced mRNA levels in Moz/ mutanttal Cell 23, 652–663, September 11, 2012 ª2012 Elsevier Inc. 653
Ao
PT
LSA
Substitute of
descending aorta
Embryonic
ventral aorta
Wild type MozΔ/Δ MozΔ/Δ
Wild type MozΔ/Δ
Right injection Left injection
Wild type MozΔ/Δ
RV LV
LARA
Ao
VS
RV LV
LARA
Ao
VS
*
3
4
6
E11.5 wild type
dAo
vAo
PaPa
SA
Ao
PT
LSA
dAo
3 3
E18.5 Moz mutant
Ao
PT
RSA RCCA
LCCA
DA
LSA
E18.5 wild type
Ao
LPA
Wild type MozΔ/Δ
OV
He
1b 2
3
He
2
1b
4
3
OV
He
1b 2
3
He
6
43
He
63
dAo dAo
3
He
2
1b
4’6
6 E10.5
E9.5
oRoR aCaC
4’
P2
PP PP
Wild type MozΔ/Δ
W
ild
 t
yp
e
M
oz
Δ/
Δ
Bs
M
P
As
Pm
Z Mx Mx
Bs
As
Z
*
*
Wild type MozΔ/Δ
G H
J
K L M
N O
P Q R
S T
X
U V
W
A
B
C D E F
I
Ao
PT
RSA
RCCA LCCA LSA
LPA
DA
Figure 1. Craniofacial, Palate, Aortic Arch, and Heart Abnormalities in MozD/D Mutant Pups
Moz+/+ (A, C, E, G, I, K, N, S, U, and W) andMozD/D (B, D, F, H, J, L, M, O, T, V, and X) newborn mouse pups (A–F), E18.5 pups (G–O), E9.5 (S and T), and E10.5
(U–X) embryos. Lateral view of the head (A and B), ventral view of the palate (C and D), and of the bone structure of the palate (E and F). Note the shortened face
and mandible of the mutant (A and B), the lack of midline fusion of the secondary palate (arrow in D and F). Asterisks in (F) indicate location where the maxillary
shelf and the palatine shelf should have fused. Aortic arch and other great vessels, ventral view, ink injected (G andH), and traced (I and J). Note the absence of the
aortic arch between the LCCA and the LSA, i.e., an IAA-B (arrow in H and J) and the connection of the pulmonary trunk with the descending aorta (H and J). Resin
cast of heart and large blood vessels (K–M) injected with red (left ventricle) and blue (right ventricle), H&E sections of hearts, ventral view (N and O). Note the
complete filling of both sides of theMozD/D hearts by injection from either the right (L) or left (M) ventricle, the ventricular septum defect (arrow in O), and overriding
aorta (asterisk in O). Schematic drawing of aortic arch development from E11.5 to E18.5 (P and Q) and abnormal vessels in E18.5MozD/Dmutants (R). Ink-injected
aorta-pharyngeal complex at E9.5 (S and T) and E10.5 (U and V). Resin cast of the aorta-pharyngeal complex at E10.5 (W and X). The connection between the
ascending and descending aspects of the aorta is derived from the left fourth pharyngeal artery (red in P and Q), missing in MozD/D (arrow, R). The left fourth
pharyngeal artery is not yet developed at E9.5 in eitherMoz+/+ orMozD/D (S and T). Note, however, the presence of a fourth PAA inMoz+/+ E10.5 embryos (U and
W), which is absent inMozD/D E10.5 embryos (40 in V and X). 1b, mandibular portion of the first pharyngeal arch; 2, second pharyngeal arch; 3, 4, 6, third, fourth,
and sixth PAA; arrowhead in (F), presphenoid bone, only visible through cleft palate; Ao, aorta; As, alisphenoid; Bs, basisphenoid; dAo, dorsal aorta; Ca, caudal;
DA, ductus arteriosus; He, heart; LA, left atrium; LCCA, left common carotid artery; LSA, left subclavian artery; LPA, left pulmonary artery; LV, left ventricle;
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Table 1. Incidence of Specific Anomalies Observed inMozD/DMutant Neonatal Mice Compared to Incidence Reported in Patients with
DGS and Tbx1 Mouse Mutants
Finding
MozD/D Mouse
Neonatesa Patients with DGS (%)b Mouse Neonates within a Series of Tbx1 Mutant Alleles (%)c
Number/
Total %
Botto et al.
(2003)
Kobrynski and
Sullivan (2007) /
Neo/
Neo /Neo2
Neo2/
Neo
Neo2/
Neo2 +/ +/Neo +/Neo2
Any major finding 33/33 100 100 – 100 100 100 100 100 – – –
Palatal anomalies 33/33 100 16 69–100 100 – – – – – 0 –
Cleft bony palate 33/33 100 – 11 100 – – – – – 0 –
Absent or hypoplastic
thymus
33/33 100 28 – 100 O O 100 100 41 O 29
Skeletal 33/33 100 9 17–19 100 – – – – – – –
Vertebrae anomalies 33/33 100 7 19 100 – – – – – – –
Cardiovascular defects 19/19 100 81 49–83 100 – – – – – – –
Cardiac defects 18/19 95 – – 100 100 100 85 – – – –
Ventricular septum defect 18/19 95 69 30–36 100 100 100 85 – – – –
Atrioventricular septum
defect
3/12 25 3 – – – – – – – – –
Aortic arch defects 14/19 74 63 – 100 100 90 O 100 38 42 11
Interrupted aortic arch 14/19 74 23 14–15 87 – – – 20 3 – 0
Right descending aorta 5/19 26 43 – 13 – – – – – – –
aData are derived from this study.
bData are derived from Botto et al. (2003), who examined 35 patients with DGS (43 with respect to some findings), and Kobrynski and Sullivan (2007),
who summarized data from multiple sources. Note the high degree of variation among patients with DGS.
cData are derived from Jerome and Papaioannou (2001), Vitelli et al. (2002), Xu et al. (2004), and Zhang and Baldini (2008). Tbx1mRNA ranges from 0%
in the Tbx1/ to 70% of wild type in the Tbx1+/Neo2. O indicates that defect is present but penetrance not stated. – indicates t hat no data are available.
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2C and 2D), which corresponds to the timing requirement of
Tbx1 for fourth PAA formation (Xu et al., 2005). One day later at
E9.5, mRNA levels of Tbx1 and Tbx5 were reduced in Moz/
mutant embryos (Figure 2E). mRNA levels of other genes,
including Nkx2-5, Gata4, and Crkl, were normal (Figures 2E–
2H). Expression levels of Tbx1 in E9.5 Moz/ mutant embryos
were approximately 50% of wild-type levels. By E10.5, mRNA
levels of Tbx1, Tbx2, and Tbx5 were reduced in Moz/ mutant
embryos (Figure 2I). Differences in Tbx1 mRNA levels were
also detectable at E11.5 as assessed by northern blot and densi-
tometry (data not shown). Of interest, given the high frequency of
PAA remodeling defects in Moz mutants, reduction of Tbx1 to
just 70% of the wild-type expression level is sufficient to result
in fourth PAA patterning defects and hypoplasia (Zhang and
Baldini, 2008).
RNA/RNA in situ hybridization of E9.5 sections and whole-
mount E10.5 embryos revealed that, whereaswild-type embryos
exhibited the previously published expression patterns (Daven-
port et al., 2003; Naiche and Papaioannou, 2003), expression
of Tbx1 was almost absent in some MozD/D mutant embryos
(Figures 3A and 3B) or was reduced (Figures 3C–3F). Similarly,
expression levels of Tbx2 (Figures 3G and 3H) and Tbx5 (FiguresM, maxillary shelf; Mx, maxilla; OV, otic vesicle; P, palatine shelf; P2, secondary p
trunk; RA, right atrium; RCCA, right common carotid artery; Ro, rostral; RSA, right
VS, ventricular septum. Z, zygomatic process. Scale bar, 5mm (A and B), 2mm (C
550 mm (N and O), 1150 mm (S and T), 290 mm (U and V), and 230 mm (W and X). n
MozD/+, and 15Moz+/+ newborn pups (G–J), n = 19MozD/D, 16MozD/+, and 17Moz
(S and T), n = 4 MozD/D, 20 MozD/+, and 13 Moz+/+ control E10.5 embryos (U–X).
Developmen3I and 3J), as well as Tbx3 (Figure S2), were reduced. Overall, the
expression analysis suggests that of the cardiac development
genes examined here, the first affected by the absence of
MOZ is Tbx1, whereas effects on Tbx5 and Tbx2 are delayed
by 24 and 48 hr, respectively.
Moz Mutant Embryos Lack H3K9ac at T box Gene Loci
We have previously shown that MOZ is required for H3K9ac
at Hox gene loci in E10.5 embryos (Voss et al., 2009). High
levels of H3K9ac are associated with the transcriptionally active
state of gene loci (Strahl and Allis, 2000). In contrast, H3K9
trimethylation (H3K9me3) is associated with transcriptional
repression, recruitment of silencing factors (Bannister et al.,
2001; Lachner et al., 2001), and DNA methylation (Este`ve et al.,
2006).
We examined histone modification levels in vivo at Tbx gene
loci (Figure 4A) in E10.5 Moz/ mutant and control embryos
by ChIP-quantitative PCR (qPCR) (Figure 4). Histone modifica-
tions were unaffected by theMozmutation at a total of six refer-
ence genes (B2m, Pgk1, Rpl13a, Hsp90ab1, Alb, Hbb; data not
shown). We observed that the levels of H3K9ac were reduced
in Moz/ mutant embryos at the Tbx1 and Tbx5 loci near the
start site of transcription (Figure 4B), 0.7–1 kb upstream of thealate; Pa, pulmonary artery; Pm, premaxilla; PP, primary palate; PT, pulmonary
subclavian artery; RV, right ventricle; SA, subclavian artery; vAo, ventral aorta;
and D), 1.5mm (E and F), 940 mm (G and H), 2.3mm (K), 1.5mm (L), 1.2mm (M),
= 33MozD/D, 45MozD/+, and 35Moz+/+ newborn pups (A–F), n = 19MozD/D,13
+/+ newborn pups (K–O). n = 12MozD/D, 14MozD/+, and 9Moz+/+ E9.5 embryos
See also Figure S1.
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Figure 2. mRNA Expression Levels of Genes Regulating Heart Development and Genes within the 22q11 Deletion Interval
(A) Schematic drawing of the genomic context of the Tbx1 gene and genes flanking the locus on chromosome 16 in the mouse, a region syntenic with the 22q11
deletion interval in human.
(B) Schematic representation of major regulators of transcription during heart development.
(C–I) mRNA expression levels as assessed by RT-qPCR and normalized to housekeeping genes inMoz+/+ andMoz/ embryos at E8.5 (C and D), E9.5 (E–H), and
E10.5 (I); mRNAs encoded by genes as indicated in the graphs. *p < 0.05 and **p < 0.01. Exact p values are given below. Significantly lower inMoz/ embryos
were mRNAs encoded by Tbx1 at E8.5 (C, p = 0.029), at E9.5 (E, p = 0.001), and E10.5 (I, p = 0.039); Tbx5 at E9.5 (E, p = 0.011) and E10.5 (I, p = 0.006) and Tbx2 at
E10.5 (I, p = 0.014). Not significantly changed were the mRNA expression levels of housekeeping genes (D and H), other genes in the 22q11 deletion interval (F),
and major regulators of heart development, Gata4 and Nkx2-5 (G). Data are presented and were analyzed as described in the Experimental Procedures. Data
were derived from 36 embryos, n = 6 Moz+/+ and 6 Moz/ per gene at each developmental stage.
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in the Tbx1 coding region (Figure 4D). In contrast to H3K9ac,
presence or absence of MOZ had no effect on H3K14ac
(Figures 4E–4G). The loss of H3K9acwas accompanied by a cor-
responding increase in the repressive H3K9 modification mark,
H3K9me3 (Figures 4H and 4I). Our data reveal a requirement
for MOZ for acetylation of H3K9 and transcriptional activity of
the Tbx1, Tbx2, and Tbx5 loci in vivo.656 Developmental Cell 23, 652–663, September 11, 2012 ª2012 ElsIn HeLa cells, MOZ associates with ING5 and acetylated
histone 3 as part of the MOZ-ING5 complex (Doyon et al.,
2006). Because ChIP-quality antibodies to MOZ are not avail-
able, we examined binding of the MOZ complex protein ING5
to Tbx loci in lieu of MOZ (Figures 4J and 4K). ING5 associated
with Tbx1 and Tbx5 in wild-type embryos showing that
components of the MOZ complex occupy these loci. In contrast,
ING5 occupancy of the Tbx1 and the Tbx5 locus wasevier Inc.
Figure 3. Reduced Expression of Tbx Genes in MozD/D Embryos
Detected by In Situ Hybridization
Moz+/+ (A, C, E, G, and I) andMozD/D (B, D, F, H, and J) embryos, whole mount
at E10.5 (A–D and G–J), and sections at E9.5 (E and F). Expression of Tbx1
(A–F), Tbx2 (G and H), and Tbx5 (I and J). Note the substantial reduction (B) or
more moderate reduction (D and F) in Tbx1 mRNA signal in the MozD/D
embryos (dark purple in whole mount), reduced Tbx1 mRNA signal in the
mesodermal core of the pharyngeal arches (black-silver grains, arrows E and
F), and in the pharyngeal endoderm (asterisks, E and F) in theMozD/D embryos
on sections. The region of the fourth pharyngeal arch is indicated (arrows,
C andD). Note the reduction in Tbx2 (G andH) and Tbx5mRNA signals (I and J,
arrowhead indicates Tbx5 expression maintained in the inflow tract at E10.5).
1a and 1b, maxillary and mandibular, respectively, aspect of the first
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Developmensignificantly reduced in embryos homozygous for the Moz null
allele, Moz/ (Figure 4J), whereas ING5 occupancy at the
Tbx2 and Tbx3 loci was not affected by MOZ (Figure 4K).
If the effects of MOZ on histone modification and expression
of the Tbx1 and Tbx5 loci were indirect, one would expect to
see all histone modification marks associated with gene activa-
tion, including H3K14ac, reduced in the Moz mutants. Our
observation that Moz mutation reduces the binding of the
MOZ complex protein ING5 to the Tbx1 and Tbx5 loci and
H3K9ac, but not H3K14ac, suggests that MOZ acts directly on
the Tbx1 and Tbx5 loci to acetylate H3K9 and regulates their
expression.
Effects of MOZ on Regulators and Targets of TBX1
To examine the regulatory network of transcription factors that
cooperate with TBX1 in heart development, we determined the
effects of loss ofMoz on a number of genes encoding transcrip-
tion factors that were reported to induce Tbx1 gene transcrip-
tion, i.e., FOXA2, FOXC1, and FOXC2 (Figure 2B; Yamagishi
et al., 2003) and a known target gene of TBX1, Pitx2 (Figure 2B;
Nowotschin et al., 2006). At E8.5, none of the forkhead genes,
Foxa2, Foxc1, or Foxc2, exhibited a reduction in mRNA levels
in the Moz/ mutant embryos. In fact, Foxc1 mRNA levels
were elevated in the Moz/ mutant embryos as compared to
controls (Figure 5A). At E9.5 and E10.5, Foxa2 mRNA levels
were not different between Moz/ mutant embryos and
controls, whereas Foxc1 and Foxc2 mRNA levels were now
reduced in the Moz/ mutant embryos (Figures 5B and 5C).
Expression of Pitx2 requires TBX1 as a transcriptional activator
(Nowotschin et al., 2006). As expected in a TBX1-deficient state,
Pitx2 mRNA levels were reduced in E9.5 and E10.5 Moz/
mutant embryos as compared to control (Figure 5D). The Chd7
gene encodes, likeMoz, a chromatin modifier, namely the chro-
modomain helicase DNA-binding protein CHD7 and interacts
genetically with the Tbx1 locus (Randall et al., 2009). In contrast
to the TBX1 target gene Pitx2, Chd7 gene expression was unaf-
fected by the mutation ofMoz (Figure 5E). Of the three forkhead
proteins, ChIP-quality antibodies could only be obtained for
FOXA2. The Tbx1 locus is regulated by forkhead transcription
factors through binding to a number of mutually redundant tran-
scription factor binding sites (Zhang and Baldini, 2010). We
examined a consensus forkhead binding site, which is more
than 14 kb upstream of exon 1 of the Tbx1 locus and highly
conserved between humans and mice (Yamagishi et al., 2003)
(for details see Supplemental Experimental Procedures). The
site was bound by FOXA2 protein, and occupancy was
increased in the Moz/ mutant embryos, as compared to
wild-type controls (Figure 5F), suggesting that the reduced
Tbx1 mRNA (or protein) levels induced recruitment of the tran-
scriptional activator to the Tbx1 locus via a feedback mecha-
nism. However, despite this increased recruitment of FOXA2 topharyngeal arch; 2, 3, 4, second, third, and fourth pharyngeal arch; 40, region
where the fourth pharyngeal arch should be present in theMozD/D; FL, forelimb
bud; He; Heart; OV, otic vesicle. Scale bar, 190 mm (A and B), 390 mm (C andD),
142 mm (E and F), 350 mm (G and H), and 530 mm (I and J). Data were derived
from 42 embryos, n = 6 Moz+/+ and 6 MozD/D per gene at E10.5 and 3 Moz+/+
and 3 MozD/D at E9.5. See also Figure S2.
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Figure 4. H3K9ac and MOZ Complex Protein ING5 Occupancy Is
Reduced at the Tbx1 and Tbx5 Gene Loci in the Absence of MOZ
(A) Schematic drawing of the genomic loci assayed for histone modifications
and ING5 occupancy by ChIP. ‘‘Tbx1_1, Tbx1_2, Tbx2_1 etc.’’ denote
sequences amplified in (B)–(K). H3K9ac (B–D), H3K14ac (E–G), H3K9me3
(H and I), and ING5 (J and K) were assessed by ChIP-qPCR of Moz/ and
Moz+/+ E10.5 embryos for sequences 0.7 to 1.0 kb upstream of the TSS
(B, E, H, and J; tiles_1), in proximity of the transcription start site (TSS; C, F, H,
J, and K; tiles_2) and in the coding region (D and G). Note the reduction in
H3K9ac inMoz/ mutants 0.7 to 1 kb upstream of the TSS of Tbx1, Tbx2,
and Tbx5 (B; p < 0.0005, p = 0.003, and p = 0.003, respectively), near the TSS
of Tbx1 and Tbx5 (C; p = 0.032 and p = 0.002, respectively), and in the Tbx1
coding region (D; p = 0.0151), but no reduction in H3K14ac (E–G) and an
increase in H3K9me3 (H and I; p = 0.0071). Notice the reduction in binding of
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658 Developmental Cell 23, 652–663, September 11, 2012 ª2012 Elsthe Tbx1 locus, Tbx1 gene transcription was approximately half
of normal in the absence of MOZ (Figure 2), indicating that MOZ
is specifically required for normal Tbx1 transcription, and the
forkhead transcription factors are unable to drive normal levels
of transcription without MOZ. The reduction in Foxc1 and
Foxc2mRNA levels at E9.5 and E10.5 conflicted with unchanged
or increased mRNA levels at E8.5, suggesting that these
were indirect consequences of loss of MOZ. Nevertheless, we
examined if MOZ affected the occupancy of the transcription
start site of the Foxc1 and Foxc2 gene by ING5, the member of
the MOZ complex. ING5 occupancy of the Foxc1 locus was
low and not significantly different in Moz/ mutant and control
embryos (Figure 5G), and ING5 did not bind to the Foxc2 locus
(data not shown), indicating that the Foxc1 and Foxc2 genes
are not direct targets of MOZ. Occupancy of the Pitx2 locus by
ING5 was not affected by the absence or presence of MOZ (Fig-
ure 5G), suggesting that the reduction in Pitx2 transcriptional
activity was an indirect effect of MOZ, presumably via reduction
of TBX1 levels.
Genetic Interaction between the Moz and the Tbx1
Locus
If deficiencies in MOZ contributed to the phenotypic variability of
velo-cardio-facial defects via a failure of activation of Tbx1 gene
expression, a genetic interaction between theMoz and the Tbx1
gene would be expected. Therefore, we examined wild-type,
Tbx1lacZ/+, and Moz+/ single- and double-heterozygous mice
for viability and anomalies. Among 148 offspring of Tbx1lacZ/+
byMoz+/ matings were only 8 Tbx1lacZ/+Moz+/ double hetero-
zygous at weaning (Figure 6A), indicating that 80% of
Tbx1lacZ/+Moz+/ double heterozygotes had died. At E17.5–
E18.5 a large proportion of Tbx1lacZ/+Moz+/ double heterozy-
gous exhibited DGS-like anomalies, significantly larger than
the frequency calculated for mere additive effects of Moz and
Tbx1 heterozygosity (Figure 6B). A total of 120 E17.5–E18.5
fetuses were examined for defects by macroscopic dissection
(Figure 6C) and 79 by serial sectioning and examination of
the heart (Figure 6D). Wild-type littermate controls showed no
anomalies. Among Moz+/ single heterozygotes we observed
RSA, great vessel wall remodeling, and craniofacial defects, as
well as minor VSDs (Figures 6B–6D). Among Tbx1lacZ/+ single
heterozygotes we saw aortic arch, RSA, and palate defects
(Figures 6B–6D). DGS-like anomalies were more frequent
and more severe in the Tbx1lacZ/+Moz+/ double heterozygotes
(Figure 6B) and included cleft palate, thymus hypoplasia,
IAA-B, and abnormal RSAs (Figure 6C) and large VSDs (Fig-
ure 6D). The more than additive rise in incidence of DGS-like
anomalies and the increase in severity in the double heterozy-
gotes demonstrate synergistic epistasis between Moz and
Tbx1 mutation.the MOZ complex protein ING5 to Tbx1 and Tbx5 in Moz/ mutants (J; p =
0.001 and p < 0.0005, respectively), but not Tbx2 and Tbx3 (K). For the effects
ofMozmutation, p values <0.05, <0.01, and <0.001 are indicated by one, two,
and three asterisks, respectively. Data are presented and were analyzed as
described in the Experimental Procedures. Data are derived from a total of 39
embryos, n = 6Moz+/+ and 6Moz/ per ChIP antibody (B–G), 3Moz+/+ and 3
Moz/ (H, I, and K), and 4 Moz+/+ and 5 Moz/ (J).
evier Inc.
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Figure 5. Expression of Genes Encoding Regulators of the Tbx1Gene, Genes Regulated by TBX1 Protein, and Genes Showing Genetic Inter-
action with the Tbx1 Locus
mRNA levels of genes as indicated assessed by RT-qPCR (A–E) and occupancy of gene loci as indicated by FOXA2 (F) and by theMOZ complex protein ING5 (G).
Expression of the genes encoding the forkhead protein FOXA2 (A–C) reported to upregulate Tbx1 gene expression, as well as the Chd7 gene (E), reported to
interact genetically with the Tbx1 locus, is unaffected byMozmutation at E8.5 (A), E9.5 (B and E), and E10.5 (C). Tbx1 locus occupancy assessed by ChIP-qPCR
by FOXA2 is increased in E9.5Moz/mutants (F; p = 0.015), albeit without being able to induce normal Tbx1 expression levels in the absence of MOZ (Figure 2).
Expression of Foxc1 is increased at E8.5 (A, p = 0.04), and expression of Foxc1 and Foxc2 is decreased at E9.5 (B, p = 0.008 and p = 0.001, respectively) and E10.5
(C, p = 0.034 and p = 0.011, respectively) inMoz/mutants without changes in occupancy of Foxc1 locus by ING5 (G; p = 0.251) and without occupancy of the
Foxc2 locus by ING5 (data not shown). The expression of the Pitx2 gene, a target gene of TBX1, is decreased at E9.5 and E10.5 inMoz/mutants (D, p = 0.023)
without changes in ING5 occupancy of the Pitx2 locus (G). For the effects of Moz mutation, p values <0.05 and <0.01 are indicated by one and two asterisks,
respectively. Data are presented andwere analyzed as described in the Experimental Procedures. Data were derived from 48 embryos, n = 6Moz+/+ and 6MozD/D
per developmental stage (A–E) and 3 Moz+/+ and 3 Moz/ (F and G).
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Transgene
Because we hypothesized that the reduction in Tbx1 transcrip-
tional activity in the Moz mutants is a mechanistic contributor
to the DGS-like defects in the Moz mutant mice, we expected
that Tbx1 overexpression might rescue the DGS-like defects of
Moz mutant mice at least partially. We generated Tbx1 BAC
transgenic mice with one exogenous copy of the Tbx1 gene,
resulting in an elevation of Tbx1 mRNA levels to 128% ± 7%
(SEM) of wild-type on the Moz wild-type background and
a rescue of Tbx1 mRNA levels to 88% ± 8% of wild-type on
the MozD/D background (n = 10 E9.5 embryos per genotype).
Although one additional copy of Tbx1 was unable to rescue the
aortic arch and palate defects, one copy of the Tbx1-containing
BAC rescued the cardiac septal defects, in all three MozD/D
Tbx1-transgenic animals examined (Figures 6E, 6F, and S3).
Examination of serial sections ofMozD/Dmutant hearts revealed
cardiac septation defects in all four MozD/D hearts in this
experiment (three with VSDs and one with an aortopulmonary
septal defect), as expected based on the septal defects
observed in 18 of 19 MozD/D mutant hearts examined in experi-
ments described above (95% penetrance, Figure 1; Table 1). In
contrast, all three MozD/D Tbx1-transgenic hearts had intactDevelopmencardiac and aortopulmonary septa. The rescue indicates that
the deficiency in Tbx1 gene expression underlies the cardiac
septal defects observed in the Moz homozygous mutant mice.
RA Increases Penetrance of DGS-like Defects
in Moz+/– Mice
We hypothesized that Moz haploinsufficiency might render an
individual sensitive to environmental influence. To test this
hypothesis, we investigated if dietary supplementation with RA
affected the incidence of DGS-like anomalies in Moz heterozy-
gotes because oversupply with vitamin A or RA has been re-
ported to cause DGS-like anomalies (Lammer et al., 1985). Of
30 mice heterozygous for the Moz null allele, three exhibited
small VSDs (Figure 6D). In contrast, none of the mice heterozy-
gous for the carboxy-terminal deletion allele MozD had DGS-
like anomalies (Figure 7A, Untreated). We used the MozD allele
because it appeared to provide just enough MOZ activity in
MozD/+ heterozygotes to prevent DGS-like defects to occur
spontaneously. We examined the effects of RA during a critical
phase of PAA and outflow tract development, i.e., from E7.25
to E9.25. Dietary RA at E7.25 had no effects on aortic arch
morphology in E17.5–E18.5 fetuses. However, dietary RA at
E8.25 and E9.5 caused DGS-like anomalies in 42% and 25% oftal Cell 23, 652–663, September 11, 2012 ª2012 Elsevier Inc. 659
Figure 6. Genetic Synergy between Moz
and Tbx1 Haploinsufficiency and Rescue
of Moz Mutant Heart Defects by a Tbx1
Transgene
(A) Survival of wild-type, Moz+/ and Tbx1+/
single-heterozygous, and Moz+/Tbx1+/ double-
heterozygous mice to weaning. Note that 80% of
Moz+/Tbx1+/ double-heterozygous mice are not
viable.
(B) Incidence of DGS-like anomalies observed in
Moz+/Tbx1+/ double- and single-heterozygous
mice at E17.5–E18.5.
(C and D) Details of DGS-like anomalies in loca-
tions other than the heart (C) and in the heart (D)
observed in the Moz+/Tbx1+/ double and single
heterozygotes.
(E and F) E18.5 offspring in three litters of
MozD/+Tbx1-Tg by MozD/+ matings. (E) Overview
and high-resolution images of VSDs in three
MozD/D animals (arrows, as in Figure 1 and Table 1)
and the rescue of the septal defects by one copy of
the Tbx1-containing BAC RP23-35B9 in three
MozD/D Tbx1-Tg animals (serial images in Fig-
ure S3). (F) Summary of all 25 offspring. The septal
defects observed in the four MozD/D were three
VSDs and one aortopulmonary septal defect. Data
are presented and analyzed as described in the
Experimental Procedures. AbRSA, abnormal right
subclavian artery including retrotracheal and
abnormal origin; GVRD, great vessel wall remod-
eling defects, i.e., dilated in diameter and thin
walled; LA, left atrium; LV, left ventricle; IAA-B,
interrupted aortic arch type B; RA, right atrium;
RV, right ventricle; VS, ventricular septum; VSD,
ventricular septal defect. Scale bar, 445 mm in the
left two panels of (E) and 185 mm in all other panels
of (E).
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11% of the RA-treated wild-type controls at E8.5 and none of the
controls at E9.5 showed DGS-like symptoms. The anomalies
observed in the RA-treated MozD/+ heterozygotes included cleft
secondary palate, hypoplasia of the thymus, abnormal RSA,
transposition of the great arteries, and IAA-B (Figure 7B).
Collectively, our findings show that homozygous mutation
of the Moz gene or Moz heterozygous mutation combined
with either Tbx1 haploinsufficiency or oversupply of RA
during pregnancy causes anomalies that resemble DGS with660 Developmental Cell 23, 652–663, September 11, 2012 ª2012 Elsevier Inc.high penetrance (40%–60% in haploid
state and 100% in the homozygous
state) and include severe defects, i.e.,
IAA-B and VSD. Importantly, one copy
of a Tbx1 transgene rescued the cardiac
septal defects in Moz homozygous
mutants.
DISCUSSION
We have shown that
(1) MOZ has highly specific functions
in the development of the palate,facial structures, thymus, and the cardiovascular system,
and lack of MOZ produces defects closely resembling
DGS.
(2) MOZ is required for normal levels of Tbx1 mRNA and
(3) normal levels of H3K9ac at the Tbx1 locus.
(4) TheMOZ complex protein ING5 binds to the Tbx1 locus in
the presence of MOZ.
(5) Homozygous mutation of Moz alone or heterozygous
mutation of Moz in combination with either
(6) Tbx1 haploinsufficiency or
Figure 7. Sensitization to RA by Loss of One
Copy of Moz
(A) Effects of RA treatment at E7.25–E9.25 on
Moz+/+,MozD/+, andMozD/D E17.5–E18.5 pups on
the incidence of DGS-like anomalies. Note the
induction of DGS-like anomalies in heterozygotes
treated with RA at E8.25 and E9.25.
(B) Details of anomalies observed in the RA-
treated MozD/+ heterozygous animals. Data are
presented and analyzed as described in the
Experimental Procedures. Abnormal RSA,
abnormal right subclavian artery including retro-
tracheal and abnormal origin; IAA type B, inter-
rupted aortic arch type B; TGA, transposition of
the great arteries.
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including IAA-B, thymus aplasia, or hypoplasia, cleft
palate, and VSD.
(8) One copy of a Tbx1 transgene rescues the cardiac septal
defects seen in Moz mutant mice.
The structures affected in the Moz mutant embryos are
derived from Tbx1-positive aspects of the pharyngeal arches
(aortic arch, thymus, palate) and the Tbx1 and Pitx2-positive
derivatives of the second heart field. One-third of newborn
Tbx1 heterozygous display minor great vessel remodeling
defects, but overt IAA-B occurs at a low frequency (Lindsay
and Baldini, 2001). However, the combination of Moz and Tbx1
haploinsufficiency generates the severe defects (IAA-B and large
VSDs) as well as other DGS-like defects at a higher frequency
than would be expected from additive effects of the two haploin-
sufficiencies, showing a synergistic effect of haploid loss of
Moz and Tbx1. Unlike other genes reported to exhibit genetic
interaction with the Tbx1 locus in causing DGS-like defects
(Fgf8,Crkl,Gbx2,Pitx2,Chrd),Moz and another chromatinmodi-
fier, Chd7, showed DGS-like defects in the single-heterozygote
state (data reported here and Randall et al., 2009 for Chd7).
Our study does not exclude the possible involvement of other
MOZ target genes. Indeed, we show here that apart from Tbx1,
the Tbx5 locus is also regulated byMOZ, albeit later than Tbx1. In
addition, we have previously shown that MOZ is required for
H3K9ac and expression of Hox loci and is critical for body seg-
ment identity specification (Voss et al., 2009). RA treatment of
Moz mutant embryos rescued Hox gene expression, H3K9ac,
and segment identity. In contrast, RA treatment enhanced the
DGS-like defects showing that the upregulation of Hox gene
expression does not ameliorate the DGS-like defects, rendering
it unlikely that the DGS-like defects were mediated by reduced
Hox gene expression in the MOZ-deficient state. The fact that
one additional copy of Tbx1 rescues the cardiac septal defects
observed in Moz mutant mice demonstrates that MOZ acts via
the Tbx1 gene in cardiac septal development. The observation
that one additional copy of Tbx1 does not rescue the aortic
arch and palate defects in Moz mutant mice suggests that one
additional copy of Tbx1 may not be sufficient but may also indi-
cate that other genes are involved in the development of these
structures in addition to Tbx1.
Discordance of anomalies is observed between monozygotic
twins with DGS (Goodship et al., 1995) and C57BL/6 inbred
Tbx1lacZ/+ mice (our own observation), showing that geneticDevelopmenfactors alone are an inadequate explanation for phenotypic vari-
ation. The effects of environmental factors mediated by chro-
matin modifications must therefore play an important role in
determining the phenotypic outcome in DGS. Although other
chromatin modifiers are known to be required for heart develop-
ment (Chang et al., 2004; Gottlieb et al., 2002; Lickert et al., 2004;
Montgomery et al., 2007; Nimura et al., 2009; Randall et al.,
2009; Shirai et al., 2002; Stankunas et al., 2008; Wang et al.,
2004), the effects of loss of these on chromatin at the Tbx1 locus
were either not examined, or no effect was observed (Gottlieb
et al., 2002; Lickert et al., 2004; Stankunas et al., 2008). In
contrast, our results show effects of a chromatin modifier,
MOZ, on the transcriptional activity through discrete changes
of the chromatin at the Tbx1 locus.
Environmental factors known to affect aortic arch and heart
development include, among others, vitamin A oversupply and
pharmacological overexposure to RA, which can mimic the
palate, VSD, thymus, and aortic arch defects seen in DGS
(Lammer et al., 1985). RA is known to suppress Tbx1 gene
expression (Roberts et al., 2005), and the phenotypic outcome
in models of DGS appears to be exquisitely sensitive to gene
dosage and time course of Tbx1 gene expression (Liao et al.,
2004; Xu et al., 2005; Zhang and Baldini, 2008). Indeed, mice
heterozygous for a hypomorphicMoz allele, which do not display
DGS-like defects, responded sensitively to oversupply of RA and
develop defects in aortic arch, thymus, and palate development,
in the time frame consistent with sensitivity to Tbx1 gene expres-
sion levels.
In conclusion, we postulate thatMOZ, via H3K9ac, drives tran-
scriptional activity of the Tbx1 locus and is essential for aortic
arch, heart, thymus, and palate development. The robust devel-
opment of these structures depends on the presence of two
copies of the Moz gene. Importantly, this system is susceptible
to perturbations both at the genetic and chromatin level and
exquisitely sensitive to environmental insults at key develop-
mental stages.EXPERIMENTAL PROCEDURES
Mice
All animal experiments were approved by the Walter and Eliza Hall Institute
Animal Ethics Committee and conducted in accordance with the Australian
code of practice for the care and use of animals for scientific purposes.
Mice heterozygous for a carboxy-terminal deletion of MOZ, MozD/+ (Thomas
et al., 2006), or carrying a Moz null allele, Moz+/ (Voss et al., 2009), on antal Cell 23, 652–663, September 11, 2012 ª2012 Elsevier Inc. 661
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Moz, H3K9 Acetylation, and Cardiovascular DefectsFVB/BalbC hybrid background were used as indicated in the text and figure
legends. Tbx1 BAC transgenic mice were generated by pronuclear microinjec-
tion of BAC RP23-35B9, which contains the Tbx1 gene at its center. Tbx1 BAC
transgenic line T1-33, which contained one copy of the Tbx1 transgene, was
used. Apart from the Tbx1 gene, the BAC contains Sept5, which is not
expressed at the relevant developmental stage, as well as Gp1bb and part
ofGnbl1. The expression of neither of these two genes is affected by the pres-
ence or absence ofMoz (Figure 2F). Although the DGS-like defects were highly
penetrant inMoz/ homozygous mice regardless of the genetic background,
Tbx1lacZ/+(Lindsay et al., 2001) and Moz+/ mice, both on a C57BL/6 back-
ground, were used for the genetic interaction studies because the penetrance
of defects in heterozygotes of both strains was largely reduced on an outbred
background. Noon following the morning observation of a vaginal mating plug
was termed E0.5. Embryos and pups were collected at the developmental
stages indicated in the text and figure legends. Palate, thymus, and aortic
arch defects were scored during dissection prior to genotyping. Extraembry-
onic membranes or tails were used for genotyping by three-way PCR as
described previously (Lindsay et al., 2001; Thomas et al., 2006; Voss et al.,
2009). Oral supplementation with all-transRA (Sigma-Aldrich; R2625) was per-
formed as described previously (Voss et al., 2009) at the developmental stages
indicated in the figures.
Expression Analysis
Whole-mount and radioactive in situ hybridization, total RNA isolation,
northern blot analysis, and densitometry were conducted using standard tech-
niques as previously described (Thomas et al., 2007; Voss et al., 2000). cRNA
and cDNA probes are listed in the Supplemental Experimental Procedures.
qPCR was performed using a Roche LightCycler 480 and SYBR Green based
detection. Details on primers are given in the Supplemental Experimental
Procedures.
ChIP
ChIP followed by qPCR was carried out as described previously (Voss et al.,
2009, 2012) using primers described in Supplemental Experimental Proce-
dures. Antibodies used for ChIP, immunoblotting, and immunofluorescence
were directed against ING5 (Abnova; H00084289-B01), FOXA2 (HNF-3b
[M-20]: sc-6554; Santa Cruz Biotechnology), H3K9ac (Millipore; Upstate 07-
352), H3K9me3 (Abcam; ab8898), and H3K14ac (Millipore; Upstate 07-353).
The histone antibodies detect the modified forms preferentially over the other
forms. Anti-IgG was used as a control in ChIP.
Statistics
Data were analyzed using Intercooled Stata 10 software. RT-qPCR and ChIP-
qPCR data are presented as standardized mean ± SEM of cDNA and gDNA
concentration normalized for the housekeeping genes Hsp90ab1, Pgk1, and
Gapdh for RT-qPCR and for either b-2-microglobulin and Hsp90b for tran-
scriptionally active loci or albumin and hemoglobin b for transcriptionally
inactive loci in the ChIP-qPCR experiments. Data were analyzed by one or
two-factorial ANOVA with a number of intact Moz alleles with or without
genomic locus as independent factors, followed by Bonferroni’s post hoc
test. Frequencies of genotypes at weaning and frequencies of DGS-like anom-
alies at E17.5–E18.5 in RA treatment experiments, genetic interaction, and
rescue studies were examined by Pearson’s chi-square test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.devcel.2012.07.010.
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